清脆的
突变体
癌症
生物
癌症研究
转移
癌细胞
免疫系统
细胞生长
细胞培养
突变
野生型
免疫学
遗传学
基因
作者
Zilu Wang,Matteo Burigotto,Sabrina Ghetti,François Vaillant,Tao Tan,Bianca D. Capaldo,Michelle Palmieri,Yumiko Hirokawa,Lin Tai,Daniel S. Simpson,Catherine Chang,Allan Shuai Huang,Elizabeth Lieschke,Sarah T. Diepstraten,Deeksha Kaloni,Chris Riffkin,David C.S. Huang,Connie S.N. Li Wai Suen,Alexandra L. Garnham,Peter Gibbs
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-10-24
卷期号:14 (2): 362-379
被引量:79
标识
DOI:10.1158/2159-8290.cd-23-0402
摘要
This study provides evidence that removal of mutant TP53, thereby deleting its reported GOF activities, does not impact the survival, proliferation, metastasis, or chemotherapy responses of cancer cells. Thus, approaches that abrogate expression of mutant TP53 or target its reported GOF activities are unlikely to exert therapeutic impact in cancer. See related commentary by Lane, p. 211 . This article is featured in Selected Articles from This Issue, p. 201.
科研通智能强力驱动
Strongly Powered by AbleSci AI